BioSpace News Archive

Journal of Pharmaceutical Analysis Articles Highlight the Potential of Nanotechnology to Detect Clinically Useful Biomolecules

The advent of nanotechnology has led to exciting innovations across all fields of healthcare.

August 26, 2022
·
3 min read
RAIsonance Releases Preliminary Results from AudibleHealth Dx Validation Study

RAIsonance, Inc., a group of AI-powered technology solutions companies, today reported the preliminary results of its AudibleHealth Dx clinical validation study.

August 26, 2022
·
7 min read
The Polypill Reduces Cardiovascular Mortality by 33% in Patients Treated After Myocardial Infarction

The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.

August 26, 2022
·
3 min read
BioCapital

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

Novavax, Inc. (Nasdaq: NVAX), today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has granted expanded conditional marketing authorization (CMA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine.

August 26, 2022
·
12 min read
FDA

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.

August 26, 2022
·
16 min read
Genetown

Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-001Pro for the treatment of Chronic Myelogenous Leukemia (CML) and issued a Study May Procced (SMP) letter.

August 26, 2022
·
6 min read
Biotech Bay

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting

Biomea Fusion, Inc. announced today the presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting, which took place August 25-27, 2022 in Los Angeles, California.

August 26, 2022
·
9 min read
Business

Aziyo Biologics Appoints Michelle LeRoux Williams, Ph.D as Chief Scientific OfficerRenown Pioneer in Regenerative Medicine to Lead Company’s Pipeline Development Initiatives

Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company announced today that Michelle LeRoux Williams, Ph.D. has been appointed Chief Scientific Officer.

August 26, 2022
·
3 min read
BioCapital

This Prostate Cancer Awareness Month, National Nonprofit Urges Early Detection as Key to Survival

ZERO – The End of Prostate Cancer is encouraging all men to learn about prostate cancer risks and promote early detection during Prostate Cancer Awareness Month (PCAM), which will begin on September 1.

August 26, 2022
·
2 min read
Lysulin Looks to Expand U.S. Retail Outlets for Blood Sugar Supplement

Lysulin, a blood sugar support dietary supplement, is now available in the U.S.

August 26, 2022
·
2 min read